Cl 2 (5 mL) was added dropwise. The mixture was stirred at 0 o C and was slowly warmed to room temperature over 1.5 h. The reaction mixture was diluted with CH 2 Cl 2 (50 mL) and washed with H 2 O (40 mL) and the organic phase was dried over Na 2 SO 4 . Upon removal of the solvent, silica gel chromatography (EtOAc/hexanes, 0-80% gradient) afforded 23d (0.6987 g, 77%). LC−MS m / z = 372.3 [M+H] + .
2-((tert-Butyldimethylsilyloxy)methyl)-1-methyl-6,7-dihydrocyclopenta[f]indol-5(1H)-one (24a).
Compound 24a was prepared from 23a according to the procedure used to prepare 24c as a yellow solid in 82% yield. LC−MS m / z = 330. 1 
2-(((tert-Butyldimethylsilyl)oxy)methyl)-1-methyl-7,8-dihydro-1H-benzo[f]indol-5(6H)-one (24b).
Compound 24b was prepared from 23b according to the procedure used to prepare 23c. To the crude metathesis product, PtO 2 (200 mg, 0.88 mmol, 0.07 equiv) was added and the mixture was hydrogenated at 1 atm of H 2 until the olefin intermediate was completely consumed. The catalyst was then filtered, the toluene was concentrated and the residue was purified by column chromatography (EtOAc/hexanes, 0-15% gradient). To a solution of this intermediate (4.04 g, 11.69 mmol) in CH 2 Cl 2 (120 mL) was added activated MnO 2 in three portions (11.4 g, 11.4 g, and 5.7 g, 118, 118, and 59 mmol) with 20 min intervals. Upon complete consumption of the starting material, the MnO 2 was filtered and washed with CH 2 Cl 2 . The filtrate was concentrated and the residue was purified by column chromatography (EtOAc/hexanes, 0-15% gradient) to afford an off-white solid (2.58 g, 64%). LC−MS m / z = 344. 5 + .
2-((tert-
Butyldimethylsilyloxy
Methyl 9-(((tert-butyldimethylsilyl)oxy)methyl)-1-(2,4-dimethoxybenzyl)-4-hydroxy-8-methyl-2-oxo-2,5,6,8-tetrahydro-1H-indolo[6,5-h]quinoline-3-carboxylate (25b).
Compound 25b was prepared from 24b according to the procedure used to prepare 25c (63%, yellow foam). LC−MS m / z = 619. 6 Compound 4a was prepared from 27a and a solution of ethylamine according to the procedure used to prepare 6a (6%, white solid 
4-Bromo-3-chloro-2-iodoaniline (A1).
To a solution of 4-bromo-3-chloroaniline (10.30 g, 49.89 mmol) in CH 2 Cl 2 (100 mL) was added AcOH (9 mL, 150 mmol) followed NIS (12.50 g, 55.60 mmol). The reaction was stirred overnight and then washed well with NaHCO 3 (aq. satd., ~100 mL) until the pH was neutral. The organic layer was washed with brine (50 mL) and dried over Na 2 SO 4 . Upon removal of the solvent, two products (~3:2 ratio by LC-MS) were separated by column chromatography (EtOAc/hexanes, 0-10% gradient) affording 4-bromo-5-chloro-2-iodoaniline (9.17 g, 55%) and 4-bromo-3-chloro-2-iodoaniline (A1) (6.25 g, 38%) as tan solids. 4-bromo-3-chloro-2-iodoaniline was taken forward into the next step. LC−MS m / z = 330. 3-(6-Amino-3-bromo-2-chlorophenyl)prop-2-yn-1-ol (A2). To solution of 4-bromo-3-chloro-2-iodoaniline (A1) (15.74 g, 47.36 mmol) in CH 3 CN (50 mL) was added propargyl alcohol (3.40 mL, 57.01 mmol) and NEt 3 (13.2 mL, 94.71 mmol). The mixture was degassed with argon before Pd(PPh 3 ) 2 Cl 2 (0.65 g, 0.93 mmol, 0.02 equiv) and CuI (0.36 g, 1.89 mmol, 0.04 equiv) were added. The reaction was heated at 70 o C for 2 h. The reaction mixture was cooled to room temperature and concentrated. EtOAc (200 mL) was added to the residue and the solid was filtered and washed with EtOAc. After concentration of the mother liquor, A2 (6.189 g, 50%) and starting material (6.131 g, 39%) was obtained after silica gel chromatography (EtOAc/hexanes, 0-60% gradient). Recovered starting material was recycled two times using the above procedure to yield a total of 9.48 g of A2 (77% overall yield). LC−MS m / z = 260. 4 Cl (aq. satd., 50 mL) and H 2 O (150 mL). The product was extracted with EtOAc (100 mL X 3). The combined organic phases were washed with brine (100 mL) and dried over Na 2 SO 4 . The solvent was concentrated and the residue was purified by column chromatography
S8
(EtOAc/hexanes, 0-50% gradient) to afford A3 which was used directly in the next step. LC−MS m / z = 260. 
2-((tert-Butyldimethylsilyloxy)methyl)-4-chloro-1-methyl-1H-indole-5-carbaldehyde (A6).
To solution of A5 (0.493 g, 1.27 mmol) in THF (5 mL) at −78 o C was added n-BuLi (2.5M in hexanes, 0.60 mL, 1.50 mmol) dropwise over ~5 min. The reaction was stirred at this temperature 10 min before DMF (0.25 mL, 3.21 mmol) was added. The mixture was stirred at −78 o C for 15 min and then quenched with NH 4 Cl (aq. satd., 5 mL). After warming to room temperature, the product was extracted with EtOAc (30 mL X 3). The combined organic phases were washed with brine (30 mL) and dried over Na 2 SO 4 . The solvent was concentrated and the residue was purified by column chromatography (EtOAc/hexanes, 0-20% gradient) to afford A6 (0. 
2-((tert-Butyldimethylsilyloxy)methyl)-1-methyl-4-vinyl-1H-indole-5-carbaldehyde (A7).
Compound A6 (0.274 g, 0.81 mmol), potassium vinyltrifluoroborate (0.22 g, 1.64 mmol), Pd(OAc) 2 (5.5 mg, 0.02 mmol, 0.03 equiv), S-Phos ligand (20 mg, 0.05 mmol, 0.06 equiv) and K 2 CO 3 (0.34 g, 2.46 mmol) were mixed together in a vial that was evacuated and backfilled with argon before dioxane (3.2 mL) and H 2 O (0.5 mL) were added. The reaction was heated at 85 o C for 2 h and then cooled to room temperature. Water (5 mL) was added to the reaction mixture and the product was extracted with CH 2 Cl 2 (15 mL X 2). The combined organic phases were washed with brine (10 mL) and dried over Na 2 SO 4 . Upon concentration of the solvent, the residue was purified by column chromatography (EtOAc/hexanes, 0-10% gradient) affording A7 as a white solid (0.170 g, 65 % 
1-(2-(((tert-

2-((tert-
2-((tert-Butyldimethylsilyloxy)methyl)-3-methyl-3,6,7,8,9,10-hexahydrocyclohepta[e]indol-6-ol (A10).
A solution of A9 (0.964 g, 2.70 mmol) in EtOAc (10 mL) was hydrogenated over 10% Pd/C (Degussa type, 100 mg) with a H 2 -filled baloon (1 atm) until complete consumption of starting material as indicated by TLC. After ~1 h, the catalyst was filtered and washed with EtOAc. The solvent was concentrated and the residue was purified by column chromatography (EtOAc/hexanes, 0-20% gradient C before TiCl 4 (1M in CH 2 Cl 2 , 1.15 mL, 1.15 mmol) was added dropwise via syringe pump over 30 min. The reaction was warmed to room temperature and then stirred overnight. The mixture was diluted with CH 2 Cl 2 (10 mL) and then quenched with NaHCO 3 (aq. satd., 5 mL). Upon vigorous shaking, the organic phase was separated using a PTFE phase separator and dried over Na 2 SO 4 . Removal of the solvent afforded the crude imine (0.858 g, ~quant) as a yellow oil, which was taken directly into the next step without purification.
Crude imine (0.858 g, 1.69 mmol) and trimethyl methanetricarboxylate (0.55 g, 2.89 mmol) were mixed together in Ph 2 O (4 mL). The stirred mixture was placed onto a pre-heated heat block at 230 o C and heated for 10 min after initial bubbling of MeOH was observed (occurs at ~160 o C internal reaction temperature). The reaction mixture was cooled to room temperature, loaded directly on a silica gel column, eluted with hexanes to remove Ph 2 O and followed by an EtOAc/hexanes gradient (0-70%) to yield A12 as a yellow foam (0.5425 g, 50% over 2 steps). LC−MS m / z = 633. 5 To a suspension of A13 (0.4048 g, 0.78 mmol) in EtOAc (2.5 mL) was added LiI (0.31 g, 2.32 mmol). The reaction mixture was heated at 60 o C for 1.5 h until complete consumption of starting material was observed. The mixture was then cooled to room temperature and acidified with aqueous 1M HCl (3 mL). The product was extracted with CH 2 Cl 2 (10 mL X 3). The organic phase was washed with brine (10 mL) and dried over Na 2 (2,4-Dimethoxybenzyl)-2-formyl-7-hydroxy-1-methyl-9-oxo-1,4,5,6,9 To a solution of A15 (139.1 mg, 0.28 mmol) in dichloroethane (2.2 mL) was added MeNH 2 solution (2M THF, 0.42 mL, 0.84 mmol) followed by AcOH (30 µL, 0.50 mmol). After stirring at room temperature for 10 min, NaBH(OAc) 3 (105 mg, 0.50 mmol) was added. The reaction was stirred at room temperature ~2 h and monitored by LC/MS until the starting aldehyde was completely consumed. The solvent was concentrated and the residue was dissolved in MeOH (6 mL) and several drops of TFA to generate a homogeneous mixture that was filtered through a PTFE micron filter and purified directly by preparative HPLC. To the intermediate reductive amination product (94.2 mg, 54%), obtained as a TFA salt, was added i-Pr 3 SiH (0.90 mL) followed by TFA (0.90 mL). )methyl)-7-hydroxy-1-methyl-9-oxo-1,4,5,6,9 , tert-butyl carbamate (1.56 g, 13.31 mmol), palladium acetate (60 mg, 0.27 mmol), S-Phos (182 mg, 0.44 mmol) and Cs 2 CO 3 (4.33 g, 13.31 mmol). The flask was purged with argon for 10 minutes and dioxane (30 mL) was added via cannula. The mixture was heated at 100 ºC for 4 h. Upon cooling to room temperature, the mixture was filtered through a plug of silica gel, washed with EtOAc (250 mL) and concentrated under reduced pressure. Purification by column chromatography (0-15% EtOAc in hexanes) gave 3.55 g (94%) of the desired product as an off-white solid. 
10-
2-((Ethylamino
tert-Butyl allyl(2-(((tert-butyldimethylsilyl)oxy)methyl)-5-formyl-1-methyl-1H-indol-6-yl)carbamate (B2).
A round bottomed flask containing B1 (4.95 g, 11.82 mmol) was purged with argon for 10 minutes and DMF (60 mL) was added via cannula. Solid NaH (710 mg, 17.74 mmol, 60 wt %) was added in one portion, and the suspension was stirred at room temperature. After 10 min, allyl iodide (2.2 mL, 23.64 mmol) was added via syringe. The solution was stirred for 15 min before being poured into H 2 O (250 mL). The product was then extracted with EtOAc (150 mL X 2), dried over Na 2 SO 4 
tert-Butyl (E)-allyl(2-(((tert-butyldimethylsilyl)oxy)methyl)-5-(1-hydroxybut-2-en-1-yl)-1-methyl-1H-indol-6-yl)carbamate (B3).
A round bottomed flask containing B2 (4.86 g, 10.59 mmol)was purged with argon for 10 minutes and THF (50 mL) was added via cannula. The solution was cooled to −78 ºC using a dry ice/acetone bath. At −78 ºC, prop-1-en-1-ylmagnesium bromide (30.0 mL, 14.83 mmol, 0.5M in THF) was added dropwise. Upon completion of the addition, the cooling bath was removed and the reaction was warmed to room temperature over 1 h. The reaction was then quenched by the addition of saturated aqueous NH 4 Cl (100 mL). The product was extracted with EtOAc (150 mL X 2), dried over Na 2 SO 4 , filtered and then concentrated under reduced pressure. The desired product was obtained as a glassy yellow solid (4.60g, 87%) which was carried on directly into the ring-closing metathesis step.
tert-Butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-5-hydroxy-1-methyl-5,8-dihydroazepino[3,2-f]indole-9(1H)-carboxylate (B4).
To a round bottomed flask was added crude B3 (2.7 g, 5.40 mmol). The flask was purged with argon for 10 min and CH 2 Cl 2 (100 mL) was added via cannula. Under argon, solid (1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)(tricyclohexyl-phosphine)ruthenium (230 mg, 0.27 mmol) was added and the mixture was stirred at 40 ºC for 3 hours. Upon consumption of the starting material, the reaction was concentrated and purified by column chromatography (0-35% EtOAc in hexanes) to give 1.63 g (66%) of the desired product as tan solid. 1 
tert-Butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-1-methyl-5-oxo-5,6,7,8-tetrahydroazepino[3,2-f]indole-9(1H)-carboxylate (B5).
To a round bottomed flask was added B4 (2.0 g, 4.40 mmol). The flask was purged with argon for 10 minutes and CH 2 Cl 2 (25 mL) was added via cannula. Under argon, solid MnO 2 (2.3 g, 27 mmol) was added and the mixture was stirred at room temperature for 2 h. Upon consumption of the starting material, the reaction was filtered through a plug of silica gel (eluting with EtOAc) and concentrated under reduced pressure. The unsaturated ketone intermediate (2.0 g, quant.) was isolated as yellow crystals which required no additional purification. LC−MS m / z = 357.2 [M+H] + (loss of Boc group).
To the unsaturated ketone intermediate (2.0 g, 4.4 mmol) was added EtOAc (20 mL) via syringe. To the stirring solution was added 10% Pd/C (200 mg) and the reaction was hydrogenated under an atmosphere of H 2 . The suspension was stirred vigorously at room temperature for 3 h. After completion by LC−MS, the mixture was filtered through a short plug of silica gel, eluting with EtOAc. The solution was concentrated under reduced pressure. Purification by column chromatography (0-40% EtOAc in hexanes) gave 1.81 g (90%) of the desired product as a light yellow foam. 1 Butyl 3-methyl 10-(((tert-butyldimethylsilyl)oxy)methyl)-1-(2,4-dimethoxybenzyl)-4-hydroxy-9-methyl-2-oxo-1,2,5,6-tetrahydropyrido[2',3':4,5]azepino[3,2-f]indole-3,7(9H)-dicarboxylate (B6).To a solution of B5 (1.76 g, 3 .84 mmol) in CH 2 Cl 2 (13 mL) was added 2,4-dimethoxybenzylamine (640 µL, 4.22 mmol) and NEt 3 (1.6 mL, 11.52 mmol). The mixture was cooled to 0 °C before a solution of TiCl 4 (1.0 M CH 2 Cl 2 , 2.5 mL, 2.49 mmol) was added dropwise via syringe pump over 30 minutes. The reaction was warmed to room temperature and stirred overnight. The resultant mixture was diluted with CH 2 Cl 2 (20 mL) and then quenched with NaHCO 3 (sat. aq., 10 mL). Following vigorous shaking, the organic phase was separated using a PTFE phase separator, dried over Na 2 SO 4 + .
7-tert-
7-(tert-Butoxycarbonyl)-1-(2,4-dimethoxybenzyl)-4-hydroxy-10-(hydroxymethyl)-9-methyl-2-oxo-1,2,5,6,7,9-hexahydropyrido[2',3':4,5]azepino[3,2-f]indole-3-carboxylic acid (B8).
To a suspension of B7 (1.16 g, 1.87 mmol) in EtOAc (6.0 mL) was added LiI (750 mg, 5.62 mmol). The reaction mixture was stirred with heating at 60 ºC until complete consumption of starting material was observed (~2 h). The mixture was then cooled to room temperature and quenched with 1M HCl (10 mL) and diluted with H 2 O. The product was extracted with EtOAc (100 mL X 2) and the combined organic phase was washed with 10% aq. Na 2 S 2 O 3 (40 mL), brine (100 mL) and then dried over Na 2 SO 4 . Upon removal of the solvent, the product (1.04 g, 92%) was obtained as a yellow solid that was used directly in the next step. 1 H), 13.54 -14.03 (m, 1 H), 15.75 (s, 1 H) .
General procedure for reductive amination and deprotection of B9. To a solution of B9 (200 mg, 0.33 mmol) in dichloroethane (3.5 mL) was added a solution of amine (0.66 mmol, 2.0 equiv.) followed by AcOH (47 µL, 0.66 mmol, 2.0 equiv.). After stirring at room temperature for 10 min, NaBH(OAc) 3 (147 mg, 0.70 mmol) was added. The reaction was stirred at room temperature for 1.5 h until the starting aldehyde was consumed. Dichloroethane was then concentrated and the residue was dissolved in MeOH (10 mL) and several drops of TFA to generate a homogeneous mixture that was filtered through a PTFE micron filter and purified directly by preparative HPLC. The crude reductive amination product was obtained as a TFA salt. To the crude intermediate was added i-Pr 3 SiH (1.0 mL) followed by TFA (1.5 mL). The resultant mixture was heated at 60 º C for 2 h. Upon complete consumption of the starting material, TFA was concentrated under reduced pressure. Addition of an HCl solution (2.0 M Et 2 O, 2.0 mL) to the oily residue led to a precipitate. The mixture was diluted with Et 2 O, and the solid was filtered and washed thoroughly with Et 2 O to obtain the amine HCl salts. -10-((isopropylamino)methyl)-9-methyl-2-oxo-1,2,5,6, 
4-Hydroxy
8-Bromo-3,4-dihydrobenzo[b]thiepin-5(2H)-one (C1).
To a solution of 3-bromothiophenol (50 g, 265 mmol) in dry DMF (500 mL) at 0 ºC was added NaH (12.7 g, 318 mmol, 60% in mineral oil). The mixture was stirred for 10 min, followed by the addition of ethyl 4-bromobutanoate (45.5 mL, 318 mmol). The cooling bath was removed and the mixture was stirred overnight. This was then diluted with water (1.5 L) and extracted with ethyl ether (300 mL X 3). The extracts were combined and washed with water (100 mL X 2), brine (100 mL) and dried over anhydrous Na 2 SO 4 . The volatiles were removed under vacuum to furnish ethyl 4-((3-bromophenyl)thio)butanoate as a light brown oil, which was used directly in the next step. To preheated PPA (600 g) at 120 ºC was added the intermediate obtained above. The mixture was well mixed and heated at 120 ºC for 2 h and then poured onto ice (1000 mL) and stirred for 0.5 h. The organic phase was extracted with CH 2 Cl 2 (300 mL X 3). The CH 2 Cl 2 extracts were combined, washed with water (200 mL X 2), satd. aqueous NaHCO 3 (300 mL) and dried over Na 2 SO 4 . The solvent was then removed by rotary evaporation and the residue was chromatographed (silica gel, EtOAc in hexanes, 0-30% gradient) to provide C1 as a light brown oil (39.9 g, 59% yield over two steps). 1 2 g, 141 mmol), (2,4-dimethoxybenzyl amine (25.9 g, 23.3 mL, 155 mmol) , and triethylamine (42.7 g, 58.7 mL, 423 mmol) in CH 2 Cl 2 (300 mL) at 0 ºC was added TiCl 4 (1M CH 2 Cl 2 , 71 mL, 71 mmol) dropwise. After the addition, the mixture was brought to room temperature and stirred overnight. The reaction was quenched with satd. NaHCO 3 solution (3 mL) and the mixture was diluted with CH 2 Cl 2 (120 mL). The CH 2 Cl 2 layer was separated using a phase separator cartridge and the aqueous layer was extracted with CH 2 Cl 2 (30 mL X 2). The combined organic phases were evaporated to dryness followed by the addition of trimethyl methanetricarboxylate (53.6 g, 282 mmol) and diphenyl ether (280 mL). This was then stirred at 230 ºC for 15 min. After cooling, the reaction was chromatographed (ethyl acetate in hexanes 0-100%) to furnish C2 as a light brown solid (47.6 g, 64%). LC−MS m /z = 532.0, 534.0 [M+H] + .
Methyl 2,4-bis(benzyloxy)-9-bromo-5,6-dihydrobenzo[2,3]thiepino[4,5-b]pyridine-3-carboxylate (C3).
A mixture of C2 (47.6 g, 89.5 mmol) was dissolved in CH 2 Cl 2 (100 mL) and treated with TFA (100 mL) for 1 h at room temperature. The volatiles were removed by rotary evaporation and the residue was triturated with water (~1 L). The precipitate was collected by filtration, washed with water and dried. The material was then dissolved in THF (600 mL) at 0 ºC, followed by the addition of benzyl alcohol (40.6 g, 38.9 mL, 376 mmol), Ph 3 P (90. 0 mmol) in DMF (5.0 mL) was added NaH (0.12 g, 3.0 mmol, 60% in mineral oil) at room temperature. The mixture was stirred for 30 min followed by the addition of MeI (0.43 g, 0.19 mL, 3.0 mmol). The reaction was then stirred for an additional 2 h. Water (5 mL) was added and the product was extracted with CH 2 Cl 2 (25 mL X 2), washed with water and dried over Na 2 SO 4 ) which were then spotted onto agar plates and CFU/mL (colony forming units per mL) was determined in duplicate by counting colonies on the agar plate after 24 hours of incubation. The kill kinetics are then represented graphically by plotting the log 10 CFUs versus time at each compound concentration.
DNA gyrase mutant expression and purification. Site directed mutagenesis to generate mutant gyrase A subunit (gyrase SD-LY ) was carried out using the Invitrogen's GeneArt site directed mutagenesis PLUS kit according to the manufacturer's protocol. Primers were generated using Invitrogen's "Oligo Designer". Accuprime pfx DNA polymerase was used for increased fidelity of the pcr reactions. Plasmid DNA pET15b containing the wild-type E. coli DNA gyrase was used as the template. After sequence verification (Genewiz) of the mutation in the pcr product, the NdeI/XmaI restriction digested fragment containing the gyrase A mutant sequence was ligated into a similarly digested plasmid pET15b. The plasmid DNA containing the mutant gyrase A subunit was then transformed into competent BL21 (ƛDE3) pLysS cells for expression and purification of the mutant gyrase A subunit.
Purification of the histidine tagged gyrase A subunit (WT or mutant), was carried out by modification of a combination of methods. 3, 4 Briefly, 1L cultures of the E. coli BL21(ƛDE3) pLysS containing the plasmid of interest (WT or mutant gyrase subunit A) was grown in LuriaBertani (LB) medium containing the selective antibiotic. Induction of the protein was carried out by adding 0.5 mM IPTG to log phase culture and allowing additional growth overnight at 18 o C. The bacterial cell pellet was allowed to incubate for 30 min on ice in 40 mL of buffer containing 20mM Tris-HCl (pH 7.9), 300 mM NaCl, 0.1% triton x-100, 10% glycerol and 0.1% (weight/vol.) lysozyme for lysis. The lysate was then briefly sonicated (2 x 10 sec bursts) to reduce viscosity and then centrifuged at 20,000 x g for 30 minutes. The soluble fraction was then mixed with 5 mL of a 50% Ni-NTA slurry which was pre-equilibrated with buffer N (20 mM Tris-HCl (pH7.9), 300 mM NaCl, 0.1% triton x-100, 10% glycerol) and allowed to equilibrate for a minimum of 1 h after which the slurry was poured into a column and the unbound proteins were collected in the flow through fraction. The Ni-NTA column was then washed with 15 to 20 column volumes of buffer N with added 50 mM imidazole and washes were collected in column volume fractions to assess the protein content by a gel electrophoresis. The gyrase subunit A was then eluted with buffer N containing 200 mM imidazole in column volume fractions. The various fractions collected were examined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and those containing the gyrase subunit A were pooled and dialyzed against 4L of TED (50 mM Tris pH 8.0, 1 mM EDTA, and 2 mM dithiothreitol). The dialysate was then subjected to anion exchange chromatography on a Mono Q HR 10/10 column (run by a FPLC system) which was equilibrated in TED buffer. The gyrase subunit A was eluted using a 1M NaCl gradient in the same buffer. Peak fractions containing the protein were pooled and concentrated using centrifugal concentrators (Millipore), and then subjected to desalting and buffer exchange by size exclusion chromatography on a Superdex 200 column equilibrated in 10 mM Tris pH 7.5, 50 mM KCl, 0.1 mM EDTA and 2 mM DTT. Peak fractions containing the protein were pooled and concentrated and stored at −80 ºC in the presence of 25% glycerol.
The purified mutant gyrase A SD-LY was then reconstituted with WT gyrase B subunit (purchased from Topogen) in a 1:1 molar ratio at 15 micromolar concentration in a storage S36 buffer (50 mM Tris-Cl pH 7.5, 100 mM KCl, 2 mM dithiotreitol, 1 mM EDTA, and 50% glycerol) before use in the enzymatic assay. For experiments comparing gyrase WT and gyrase SD-LY , gyrase WT holoenzyme used was also reconstituted using a similarly purified WT gyrase subunit A, along with gyrase subunit B.
DNA gyrase assay. Microtitre plate based supercoiling assay for E. coli DNA gyrase WT or mutant was carried out as described. 5 Briefly, black streptavidin coated 96-well microplates (Pierce) were rehydrated and washed three times in wash buffer (20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 0.01% bovine serum albumin, 0.05% Tween-20). 100 µL of 500 nM biotinylated TFO1 (triplex forming oligonucleotide) was immobilized onto the streptavidin plate. Excess oligonucleotide was washed off using the wash buffer. 30 µL enzyme reactions containing 1 µg relaxed plasmid DNA (pNO1 from Inspiralis) in 35 mM Tris-HCL (pH 7.5), 24 mM KCl, 4mM MgCl2, 2mM DTT, 1.8 mM spermidine, 1mM ATP, 6.5% glycerol, 0.1 mg/ml albumin, and 1 U of E. coli DNA gyrase (Topogen) was incubated at 37 o C for 30 minutes. 100 µL of TF buffer (50 mM sodium acetate, pH 5.5, 50 mM NaCl, 50 mM MgCl 2 •6 H 2 O) was then added to the reaction and the entire mixture was transferred to the microplate wells after the TFO1 immobilization process. The microplate was incubated at room temperature for 30 min to allow triplex formation. Any unbound plasmid was washed off with 3 X 200 µL of TF buffer, then 200 uL of 1X SYBR Gold in 10 mM Tris-HCl (pH 8.0), 1 mM EDTAwas added and allowed to stain for 20 min. Fluorescence was read using the EnVision plate reader.
Topoisomerase IV activity. Decatenation assays using purified topoisomerase IV protein were performed using the DNA topo IV assay kit (Profoldin) according to the manufacturer's protocol. Decatenation of kinetoplast concatenated DNA (Profoldin) was assayed in a total reaction volume of 20 µl containing 40 mM Tris pH 7.5, 6 mM MgCl 2 , 10 mM DTT, 100 mM potassium glutamate, 50 mg/ml acetylated BSA, 1 mM ATP, and 0.2 mg kDNA substrate. Compound titrations in DMSO were added and the reactions were initiated with 2 units of E. coli topoIV (Topogen) that were incubated in a 96 well plate with shaking for 30 min at 37 o C. Upon quenching the reaction with EDTA, the assay mixture was filtered using a 96 well filterplate (Millipore) to separate the decatenated DNA product from the substrate kDNA. The decatenated product was then quantified using picogreen fluorescence on an EnVision plate reader.
Human Topoisomerase II decatenation activity was assayed similar to that described for the E. coli topoisomerase IV in a 96-well plate based format, except that 1 unit of human topoisomerase II (Topogen) was used.
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All animal studies were performed under IACUC approved protocols at AAALACcertified animal facilities.
Pharmacokinetic studies in mice
The pharmacokinetics of test compounds was evaluated in CD-1 mice. Compounds were dosed at 10 mg/kg IV in 10% DMSO and 1% Tween 80 in pH 8.0 phosphate buffer in CD-1 mice. Blood was collected by terminal cardiac puncture (3 mice per time point) at 0.083, 0.25, 1, 2, 4, 7, 16, and 24 hours after dosing. Plasma drug levels were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Briefly, the plasma samples were treated with acetonitrile-methanol mixture containing an internal standard that is a close analog of the test compounds. Pharmacokinetic parameters were calculated using a noncompartmental model using WinNonlin (Phoenix, Pharsight; St. Louis MO).
Mouse model of bacterial-induced lethality
The mice were made neutrophil-deficient with the use of cyclophosphamide IP administration at 150 mg/kg Day -4 and 100 mg/kg cyclophosphamide on Day -1. CD-1 mice were inoculated with Gram negative bacteria (E. coli, 1x10 6 CFU/mouse) mixed with 5% mucin and injected intraperitoneally. Morbidity and mortality was monitored twice per day. Moribund mice were euthanized.
